{"id":"W1983697728","doi":"10.2165/11596340-000000000-00000","title":"Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients","year":2011,"lang":"en","type":"article","venue":"Drugs in R&D","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Darunavir; Raltegravir; Ritonavir; Medicine; Maraviroc; Viral load; Regimen; Adverse effect; Internal medicine; Integrase inhibitor; Clinical endpoint; Gastroenterology; Virology; Pharmacology; Randomized controlled trial; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001164909,0.0003677427,0.001243213,0.0001380974,0.0001676019,0.0007563781,0.0003542632,0.0005181872,0.003613671],"category_scores_gemma":[0.001281711,0.0002132477,0.0008480263,0.0001951428,0.000325905,0.0004213242,0.0002152464,0.001362951,0.0003398113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002900386,"about_ca_system_score_gemma":0.000521871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002303077,"about_ca_topic_score_gemma":0.0007651002,"domain_scores_codex":[0.9996257,0.0002145156,0.00003371518,0.00004958075,0.00002288345,0.00005361643],"domain_scores_gemma":[0.9989692,0.0003760405,0.00020488,0.00005941271,0.00004036761,0.0003502169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9202097,0.004097286,0.00826049,0.0005951935,0.001088378,0.0001185748,0.00008544834,0.001162563,0.003507572,0.0002198623,0.001142296,0.05951252],"study_design_scores_gemma":[0.697397,0.2670051,0.02681735,0.0001776157,0.001492116,0.0003992669,0.00008471191,0.002354286,0.001320709,0.000639518,0.002280838,0.00003156608],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924946,0.004480431,0.0002009233,0.0003101839,0.0001382866,0.0002656752,0.0003704921,0.00002170396,0.001717693],"genre_scores_gemma":[0.9964592,0.001366066,0.0004164654,0.0004451893,0.0002019372,0.000206578,0.0003955391,0.000003796505,0.0005051909],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003613671,"threshold_uncertainty_score":0.01208895,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04272275973899473,"score_gpt":0.290875164831624,"score_spread":0.2481524050926293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}